Official Title
Use of Ivermectin as a Therapeutic Option for Patients With COVID-19
Brief Summary

confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt

Status
Unknown status
Conditions
COVID
Interventions

Drug: Ivermectin

3 successive days ttt of ivermectin started within 48 hours of symptoms

Eligibility Criteria

Inclusion Criteria:

COVID-19 patients during period of the study more than 18 years old

Exclusion Criteria:

refuse to participate pregnancy or lactation hypersensitivity to ivermectin receive any
drug with interaction with ivermectin

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 70 Years
Countries
Egypt
Locations

Waheed Shouman
Zagazig, Sharkia, Egypt

Investigator: Waheed Shouman, MD
Contact: +201114812048
shouman66@gmail.com

Contacts

Waheed Shouman, MD
+201114812048
shouman66@gmail.com

Sponsors / Collaborators
Zagazig University
NCT Number
NCT04445311
MeSH Terms
Ivermectin